CDIO Director Granted 1,736 Options at $3.60 鈥� Form 4 Filing

Q: What did CDIO director Peter K. Fung acquire according to the Form 4?

He received 1,736 stock options to buy CDIO common shares.

Q: What is the exercise price and expiration date of the newly granted options?

The options are exercisable at $3.60 per share and expire on 06/30/2035.

Q: How many derivative securities does Fung hold after this transaction?

He directly owns 2,443 stock options following the grant.

Q: Were any common shares of Cardio Diagnostics bought or sold?

No. The filing reports only an option grant; no common stock transactions were disclosed.

Q: When was the transaction and when was the Form 4 filed?

The transaction occurred on 06/30/2025, and the form was signed on 07/02/2024.

[Form 4] Everi Holdings Inc Insider Trading Activity

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Cardio Diagnostics Holdings Inc. (CDIO) 鈥� Form 4 insider filing

Director Peter K. Fung reported the grant of 1,736 stock options on 06/30/2025. Each option carries an exercise price of $3.60 and will expire on 06/30/2035. The filing indicates the transaction code 鈥淎,鈥� denoting an acquisition rather than a sale. After this award, Fung directly holds 2,443 derivative securities (stock options) linked to CDIO common stock. No open-market purchases or disposals of common shares were disclosed.

Positive

Director received 1,736 new stock options at an exercise price of $3.60, raising his derivative stake to 2,443 options

Negative

None.

Insights

TL;DR 鈥� Routine option grant; modestly positive insider signal, immaterial to fundamentals.

The Form 4 shows a standard equity incentive: 1,736 options at $3.60 awarded to Director Peter K. Fung, increasing his direct derivative position to 2,443. Because this is a grant (code 鈥淎鈥�) rather than an open-market purchase, cash outlay is zero and immediate balance-sheet impact negligible. Still, option grants slightly align director incentives with shareholders. No disposition of common shares suggests the director is not reducing exposure. Given the small size of the award and lack of cash transaction, the filing is not materially impactful to CDIO鈥檚 valuation but can be read as a neutral-to-positive governance signal.

07/02/2025 - 07:09 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TAYLOR RANDY L

(Last)

(First)

(Middle)

7250 S. TENAYA WAY

SUITE 100

(Street)

LAS VEGAS

89113

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Everi Holdings Inc. [ EVRI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/01/2025		D		744,822⁽¹⁾⁽²⁾	D	$14.25⁽¹⁾⁽²⁾	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$1.46	07/01/2025		D			100,000	⁽³⁾	05/13/2026	Common Stock	100,000	$1.46	0	D
Stock Option	$3.29	07/01/2025		D			69,960	⁽³⁾	03/08/2027	Common Stock	69,960	$3.29	0	D
Stock Option	$3.29	07/01/2025		D			142,040	⁽³⁾	03/08/2027	Common Stock	142,040	$3.29	0	D
Restricted Stock Units	⁽⁴⁾	07/01/2025		D			16,666	⁽⁴⁾	⁽⁴⁾	Common Stock	16,666	⁽⁴⁾	0	D
Restricted Stock Units	⁽⁴⁾	07/01/2025		D			22,233	⁽⁴⁾	⁽⁴⁾	Common Stock	22,233	⁽⁴⁾	0	D
Restricted Stock Units	⁽⁴⁾	07/01/2025		D			65,866	⁽⁴⁾	⁽⁴⁾	Common Stock	65,866	⁽⁴⁾	0	D
Restricted Stock Units	⁽⁴⁾	07/01/2025		D			114,280	⁽⁴⁾	⁽⁴⁾	Common Stock	114,280	⁽⁴⁾	0	D
Restricted Stock Units	⁽⁴⁾	07/01/2025		D			280,700	⁽⁴⁾	⁽⁴⁾	Common Stock	280,700	⁽⁴⁾	0	D
Performance Stock Units	⁽⁵⁾	07/01/2025		D			148,200	⁽⁵⁾	⁽⁵⁾	Common Stock	148,200	⁽⁵⁾	0	D
Performance Stock Units	⁽⁵⁾	07/01/2025		D			171,420	⁽⁵⁾	⁽⁵⁾	Common Stock	171,420	⁽⁵⁾	0	D

Explanation of Responses:

1. This Form reports securities disposed of pursuant to certain transactions (the "Proposed Transaction") contemplated by the definitive agreements Everi Holdings Inc. (the "Company") entered into on July 26, 2024 with International Game Technology PLC, a public limited company incorporated under the laws of England and Wales ("IGT"), Ignite Rotate LLC, a Delaware limited liability company and a direct wholly owned subsidiary of IGT ("Spinco"), Voyager Parent, LLC, a Delaware limited liability company ("Buyer"), and Voyager Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Buyer ("Buyer Sub"). These definitive agreements entered into by the parties in connection with the Proposed Transaction include, among others, an Agreement and Plan of Merger, dated as of July 26, 2024, by and among IGT, Spinco, the Company, Buyer, and Buyer Sub (the "Merger Agreement").

2. (cont'd from Footnote 1) Pursuant to the Merger Agreement and the other definitive agreements, on July 1, 2025 (the "Effective Time"), the Company became a wholly-owned subsidiary of Buyer. At the Effective Time, each share of the Company's common stock held by the reporting person was converted into the right to receive $14.25 in cash consideration, without interest in accordance with the Delaware General Corporation Law.

3. Pursuant to the Merger Agreement, each option to purchase shares of the Company's common stock, whether vested or unvested (each, an "Option") that is outstanding and unexercised immediately prior to the Effective Time was canceled and automatically converted into a right to receive a cash payment equal to the excess, if any, of (a) $14.25 over the per share exercise price of such Option, multiplied by (b) the number of shares of the Company's common stock covered by such Option immediately prior to the Effective Time, payable subject to the same time-based vesting terms and as in effect for such Option immediately prior to the Effective Time and in accordance with the terms of the Merger Agreement.

4. Pursuant to the Merger Agreement, each of the Company's restricted stock units (each, an "RSU") that is outstanding as of immediately prior to the Effective Time was canceled and automatically converted into a right to receive a cash payment equal to the product of (a) $14.25 and (b) the number of shares of the Company's common stock subject to each such RSU, payable subject to the same time-based vesting terms and otherwise substantially the same terms and conditions as in effect for such RSU immediately prior to the Effective Time.

5. Pursuant to the Merger Agreement, each of the Company's performance share units which vests based in whole or in part on the achievement of specified performance objectives (each, a "PSU") that is outstanding as of immediately prior to the Effective Time was canceled and automatically converted into a right to receive a cash payment equal to the product of (a) $14.25 and (b) the number of shares of the Company's common stock subject to each such PSU (based on the achievement of 100% of performance under each such PSU), payable subject to the same time-based vesting terms and otherwise substantially the same terms and conditions as in effect for such PSU immediately prior to the Effective Time (excluding any terms related to performance which were fixed as of the Effective Time).

	/s/ Randy L. Taylor by Todd A. Valli, Attorney-in-Fact	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What did CDIO director Peter K. Fung acquire according to the Form 4?

He received 1,736 stock options to buy CDIO common shares.

What is the exercise price and expiration date of the newly granted options?

The options are exercisable at $3.60 per share and expire on 06/30/2035.

How many derivative securities does Fung hold after this transaction?

He directly owns 2,443 stock options following the grant.

Were any common shares of Cardio Diagnostics bought or sold?

No. The filing reports only an option grant; no common stock transactions were disclosed.

When was the transaction and when was the Form 4 filed?

The transaction occurred on 06/30/2025, and the form was signed on 07/02/2024.

AG真人官方

[Form 4] Everi Holdings Inc Insider Trading Activity

Insights

FAQ

What did CDIO director Peter K. Fung acquire according to the Form 4?

What is the exercise price and expiration date of the newly granted options?

How many derivative securities does Fung hold after this transaction?

Were any common shares of Cardio Diagnostics bought or sold?

When was the transaction and when was the Form 4 filed?

NYSE:EVRI

EVRI Rankings

EVRI Latest News

EVRI Latest SEC Filings

EVRI Stock Data

AG真人官方

Trending News

[Form 4] Everi Holdings Inc Insider Trading Activity

Insights

Financial Analyst neutral

FAQ

What did CDIO director Peter K. Fung acquire according to the Form 4?

What is the exercise price and expiration date of the newly granted options?

How many derivative securities does Fung hold after this transaction?

Were any common shares of Cardio Diagnostics bought or sold?

When was the transaction and when was the Form 4 filed?

NYSE:EVRI

EVRI Rankings

EVRI Latest News

EVRI Latest SEC Filings

EVRI Stock Data